scispace - formally typeset
P

Pierre Bey

Researcher at Curie Institute

Publications -  114
Citations -  4741

Pierre Bey is an academic researcher from Curie Institute. The author has contributed to research in topics: Brachytherapy & Radiation therapy. The author has an hindex of 36, co-authored 114 publications receiving 4478 citations.

Papers
More filters
Journal ArticleDOI

Conformity index: A review

TL;DR: A critical analysis of the conformity indices described in the literature and an evaluation of their field of application are presented and the future of conformal index in everyday practice remains unclear.
Journal ArticleDOI

70 Gy versus 80 Gy in localized prostate cancer: 5-year results of GETUG 06 randomized trial.

TL;DR: High-dose radiotherapy provided a better 5-year biochemical outcome with slightly greater toxicity, and the subgroup analysis showed a better biochemical outcome for the higher dose group with an initial prostate-specific antigen level >15 ng/mL.
Journal ArticleDOI

A glossary for reporting complications of treatment in gynecological cancers

TL;DR: This paper contains the definition and scoring for each type of complication, general guidelines for their use, and the rationale of the glossary leaves it open for as yet undescribed types of complications.
Journal ArticleDOI

Is prophylactic para-aortic irradiation worthwhile in the treatment of advanced cervical carcinoma? Results of a controlled clinical trial of the EORTC radiotherapy group.

TL;DR: Routine para-aortic irradiation for all high risk patients with cervical carcinoma is of limited value, but patients with a high probability of local control can benefit from extended field irradiation, despite an increase in severe digestive complications.
Journal ArticleDOI

Prognostic implications of downstaging following preoperative radiation therapy for operable T3-T4 rectal cancer.

TL;DR: Downstaging after preoperative irradiation in this retrospective study results in an improvement in local control and survival in patients with non-metastatic resectable rectal cancer.